Last reviewed · How we verify
IPV at 14 and 22 weeks of age, Rotarix
IPV (inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.
IPV (inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease. Used for Prevention of poliomyelitis (IPV component), Prevention of rotavirus gastroenteritis (Rotarix component).
At a glance
| Generic name | IPV at 14 and 22 weeks of age, Rotarix |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
IPV contains chemically inactivated poliovirus particles that trigger humoral and cell-mediated immune responses without causing disease. Rotarix is a live attenuated rotavirus vaccine that replicates in the intestinal tract, inducing mucosal and systemic immunity. Both vaccines work by priming the adaptive immune system to recognize and neutralize the respective pathogens upon natural exposure.
Approved indications
- Prevention of poliomyelitis (IPV component)
- Prevention of rotavirus gastroenteritis (Rotarix component)
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Diarrhea (Rotarix)
- Vomiting (Rotarix)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: